Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of formulations containing halogenated volatile anesthetics for the preparation of formulations for the treatment of patients whose tissues have ischemic events by parenteral administration

A technology of volatile, anesthetics, applied in the field of application of preparations containing halogenated volatile anesthetics in the preparation of preparations for the treatment of patients with ischemic events in tissues by parenteral administration, capable of solving unawareness, Unaware of issues such as tissue protection of parenteral preparations

Inactive Publication Date: 2011-12-21
BAXTER INT INC
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the art is unaware of the need to use such parenteral formulations for tissue protection, especially outside of surgical anesthesia to obtain such tissue protection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of formulations containing halogenated volatile anesthetics for the preparation of formulations for the treatment of patients whose tissues have ischemic events by parenteral administration
  • Use of formulations containing halogenated volatile anesthetics for the preparation of formulations for the treatment of patients whose tissues have ischemic events by parenteral administration
  • Use of formulations containing halogenated volatile anesthetics for the preparation of formulations for the treatment of patients whose tissues have ischemic events by parenteral administration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Embodiment 1: the preparation of intravenous HVA preparation

[0064] In this example, the preparation of a sevoflurane emulsion formulation is specifically described. A similar approach was used for formulations containing enflurane, isoflurane and desflurane (see below).

[0065] Prepare the oil phase:

[0066] The container and its stirring device are tared together.

[0067] Refined soybean oil is added to it.

[0068] Heat the oil to approximately 50±5°C.

[0069] Add lecithin to the oil phase container.

[0070] Mix the contents until the lecithin is completely dissolved.

[0071] The temperature of the oil / lecithin is adjusted to about 22±2°C and maintained at this temperature.

[0072] Add the required amount of sevoflurane and maintain the temperature at 22±2°C.

[0073] Prepare the water phase

[0074] The vessel used to prepare the aqueous phase and its stirring device are tared together.

[0075] Add required water for injection to the water phase...

Embodiment 2

[0096] Embodiment 2: Intravenous use of desflurane, enflurane, isoflurane and sevoflurane on myocardial infarction in rabbits cumulative impact

[0097] These experiments were designed to demonstrate the effect of intravenous administration of different HVAs (enflurane, isoflurane, sevoflurane, and desflurane) in emulsion on myocardial infarct size after ischemia and reperfusion in rabbits. routine preparation

[0098] Male New Zealand White rabbits weighing between 2.5 and 3.0 kg were anesthetized with intravenous sodium pentobarbital (30 mg / kg). Additional doses of pentobarbital were titrated as needed to ensure loss of foot and eyelid reflexes throughout the trial. A tracheotomy is performed through a midline incision in the abdomen, and the trachea is catheterized. Using an air-oxygen mixture (FiO 2 = 0.33) to ventilate the rabbits. Maintain arterial blood gas tension and acid-base status within normal physiological ranges (pH 7.35-7.45, PaCO 2 25-40mmHg, and PaO...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is a method of treating a patient having a tissue that is subject to an ischemic event. The method is conducted by parenterally administering a formulation containing a halogenated volatile anesthetic in an amount effective to improve the tissue's resistance to or tolerance of the ischemic event. In preferred embodiment of the invention, the amount of the formulation administered to the patient is sub-anesthetic. The formulation can be administered prior to, concurrently with, or after the ischemic event. The method can be used, for example, for treatment of patients having myocardial or neuronal tissue that is subject to an ischemic event.

Description

[0001] This application is a divisional case of the international application PCT / US2003 / 031826, which entered the Chinese national phase on April 11, 2005, with the application number 200380101225.6 and the title of the invention "Method for protecting the heart and nerves by intravenous administration of halogenated volatile anesthetics" Apply. [0002] This application claims priority to US Provisional Patent Application Serial No. 60 / 417,934, filed October 11, 2002, the contents of which are incorporated herein by reference as if fully set forth herein. technical field [0003] The present invention relates to a method of improving tissue tolerance and resistance to ischemic events in a patient by administering to the patient an intravenous formulation comprising an effective amount of a halogenated volatile anesthetic (HVA). Background technique [0004] Preclinical and clinical evidence suggests that HVAs (eg, halothane, methoxyflurane, isoflurane, enflurane, desfluran...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/08A61K31/02A61K9/107A61P9/10A61K47/24A61K47/44
CPCA61K47/44A61K47/24A61K31/02A61K9/0019A61K9/1075A61P1/04A61P1/16A61P13/12A61P25/20A61P25/28A61P27/02A61P9/00A61P9/02A61P9/10A61P9/14
Inventor 劳尔·特里洛拉尔夫·莱瑟萨蒂什·佩亚韦尔纳夫尼特·普里
Owner BAXTER INT INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com